“Getting Closer to the End”: Scolyer’s Brave Cancer Battle Continues

A heartbreaking admission from one of Australia’s most respected medical minds

Renowned Australian pathologist and former Australian of the Year Professor Richard Scolyer has spoken candidly about the progression of his aggressive brain cancer, revealing that his fight is now “getting closer to an end point”.

The respected scientist, who was diagnosed with glioblastoma in 2023, shared the emotional update while reflecting on a journey that has defied medical expectations for nearly two years.

Initially given just six to eight months to live, Scolyer instead went on to survive far beyond that prognosis after undergoing pioneering experimental immunotherapy treatment — a world-first approach that drew global attention from the oncology community.

But earlier this year, the cancer returned.

Now, speaking with characteristic honesty, he says the situation has become increasingly difficult.

“I had a great period after I was initially diagnosed and could enjoy life, but I’ve had a few recurrences of the tumour,” he said.

“I guess there’s an end point, and who knows how far it is away. But we’re definitely getting closer.”

A public journey marked by courage and science

Scolyer’s illness has unfolded not just as a personal battle, but as a landmark medical case closely followed by researchers around the world. Known for his groundbreaking work in melanoma research alongside colleague Georgina Long, he was jointly named Australian of the Year in 2024 for transforming survival outcomes in advanced melanoma patients.

Despite his diagnosis, he chose to become part of an experimental treatment program, hoping that his case could help push forward new approaches to brain cancer therapy.

For a time, it appeared to work.

The tumour was held back significantly longer than expected, offering hope to both his medical team and patients facing similar diagnoses.

However, glioblastoma remains one of the most aggressive and complex cancers known, and recurrence is unfortunately common even after intensive treatment.

Standing beside Australia’s leadership

In recent days, Scolyer appeared alongside Prime Minister Anthony Albanese during an announcement honouring his contribution to cancer research.

The federal government revealed funding of $5.9 million to establish a new research position named the Richard Scolyer Chair in Brain Cancer Research, based at Chris O’Brien Lifehouse in Sydney.

The role aims to accelerate clinical trials, expand brain cancer research, and improve outcomes for patients facing one of the deadliest forms of cancer.

Even as the honour was announced, Scolyer reportedly expressed humility about having his name attached to the position.

According to the Prime Minister, he was still questioning whether it should carry his name just moments before the announcement.

“It really does say something about the humility of this extraordinary gentleman,” Albanese said.

A legacy inspired by loss and purpose

The naming of the chair carries deep emotional significance for Scolyer, who reflected on the influence of the late Professor Chris O’Brien — the renowned head and neck surgeon after whom the Lifehouse is named.

O’Brien himself died after a three-year battle with an aggressive brain tumour, and had a profound impact on Scolyer’s career and outlook.

“He mentored me, we researched together, we did a lot of things,” Scolyer said.

“For him to end up getting brain cancer and passing away from it, and then to follow in his footsteps many years down the track has been heartbreaking.”

The connection between the two men now forms a symbolic thread in Australia’s ongoing fight against brain cancer — one shaped by both personal loss and scientific determination.

Life beyond the diagnosis

Despite the seriousness of his condition, Scolyer has continued to remain active in public life and advocacy.

Earlier this year, he completed the City2Surf run in Sydney in two hours and 21 minutes — an achievement that surprised many given his ongoing treatment and prognosis.

Those close to his work say his determination has helped inspire renewed focus on brain cancer research across Australia, particularly in experimental immunotherapy and combination treatment approaches.

“I want to make a difference”

Even as he acknowledges the reality of his condition, Scolyer remains focused on impact rather than personal recognition.

He has repeatedly emphasised that the naming of the research position is secondary to the outcomes it may achieve for future patients.

“I want to make a difference for people, and I’ve dedicated my life to doing that,” he said.

“My name to it or not, that’s not where the difference happens.”

He also noted that many of the challenges surrounding brain cancer — long considered difficult to treat — are now being re-examined thanks to advances in science and clinical trials.

“So I sincerely hope that’s what happens over the next few years,” he added.

A nation watching a scientific pioneer’s final chapter

As Australia continues to follow his journey, Professor Richard Scolyer remains both a patient and a pioneer — someone whose personal struggle has become inseparable from the broader mission to transform brain cancer treatment.

His words now carry a quiet weight, reflecting both acceptance and resolve.

“I guess there’s an end point,” he said.

“But we’re definitely getting closer.”